Offering integrated artificial intelligence (AI) and seamless multi-nuclei imaging capabilities, the new magnetic resonance imaging (MRI) system reportedly enhances image quality and workflow efficiency.
Philips has garnered 510(k) clearance from the Food and Drug Administration (FDA) for the new MR 7700 3.0T MR system, which enables radiologists to obtain six different clinically relevant nuclei across anatomies.
In addition to seamless integration of multi-nuclei capabilities for enhanced anatomical and metabolic/functional imaging, the MR 7700 system reportedly achieves 20 percent more functional magnetic resonance imaging (fMRI) volume and 50 percent more diffusion tensor imaging (DTI) directions, facilitating an improved level of detail with high-resolution images, according to Philips.
The company adds that the system’s XP gradient coils allow radiologists to reduce scanning times by 35 percent and bolster signal-to-noise ratios by up to 35 percent.
“The low effort required for modifying scan parameters and protocols supports fast and easy experimentation with imaging techniques,” noted Walter Heindel, MD, a professor of radiology and chairman of the Department of Radiology at the University Hospital Münster in Germany. “These latest features clearly help improve our patient and staff experience.”
Philips said the system’s combination of ultra-high gradients and artificial intelligence (AI)-powered patient sensing and motion detection gives radiologists a unique tool to help address increased imaging volume and expectations.
“Enhanced with ultra-high gradients and artificial intelligence, Philips MR 7700 is built to deliver on the high-quality clinical performance expectations of today, and to facilitate the most demanding and promising research programs that will help drive the future of MR imaging, without sacrificing workflow efficiency or wide-bore patient comfort,” said Arjen Radder, the general manager of Magnetic Resonance and Diagnostic X-ray at Philips.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.